Identifies themes and clusters of stock movements
Market TodayThemes and Stocks AnalysesThematic Stock SearchClick here for daily refresh schedule
VXRT - Vaxart, Inc.
$7.12
0.71(11.17%)8:59:06 PM 11/23/2020
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Stock Chart

Summary:

  • MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Related Peers

Stock news

    11/16/2020VXRT
    Analysts Pound the Table on This ‘Strong Buy’ Coronavirus Stock

    A journey of a thousand miles begins with a single step, and a big one in this case. Last week, COVID vaccine researcher Vaxart (VXRT) reported preclininal study results suggesting ingestion of its oral coronavirus vaccine VXA-CoV2-1 helped to reduce viral loads in lab hamsters. Indeed, according to Vaxart, the new vaccine appeared to provoke "a broader immune response that has the potential to offer superior protection against SARS-CoV-2," than comparable injectable vaccines. Moreover, because ...

    11/16/2020VXRT
    Coronavirus Vaccine Trials Latest Updates: Moderna, Inovio

    At least 10 coronavirus-vaccine candidates are in late-stage studies, according to the Regulatory Affairs Professionals Society.

    11/16/2020VXRT
    Vaxart Hosting Key Opinion Leader Panel Call for Investors

    Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics: COVID-19: Immunity & Immunological Memory Norovirus: Disease Burden & Prevention. The Current Status of Vaccine Development Mucosal Immunity and the importance of secretory IgA Administration and Logistical Advantages of a PillInvestor Panel Being Held on Thursday, November 19th @ 12pm Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a cli...

    11/16/2020VXRT
    Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below: * Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020 Management will de...

    11/12/2020VXRT
    Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

    Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge modelRestarting the Norovirus programSOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate updat...

    11/12/2020VXRT
    Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate

    The tiny biotech's COVID-19 vaccine has generated excitement because it's a pill instead of a shot, which gives it a number of important advantages.

    11/12/2020VXRT
    Why Vaxart Stock Is Skyrocketing Today

    Shares of Vaxart (NASDAQ: VXRT) were skyrocketing 21.4% higher as of 11:22 a.m. EST on Thursday. The big gains came after the drugmaker announced promising additional data from a preclinical study of its experimental oral COVID-19 vaccine. Vaxart reported a significant reduction in lung viral loads for hamsters that received two doses of its oral vaccines and were exposed to SARS-CoV-2, the coronavirus that causes COVID-19, compared to non-vaccinated hamsters.

    11/12/2020VXRT
    Vaxart Shares Jump on Promising Data for Its COVID-19 Vaccine

    The biotech says its room-temperature-stable oral tablet vaccine would be a more practical solution to the coronavirus pandemic.

    11/12/2020VXRT
    Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine

    Robust Immune Response and Significantly Reduce Viral LoadSOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study: * Significant reduction in lung viral load of 4-5 logs in hamsters that received two oral vaccine doses, as compared to non-vaccinated animals. * Pote...